Samyukta Mullangi, MD, MBA, medical director at Thyme Care, explained her excitement to meet with industry leaders, share best practices, and learn about new innovations in oncology care at Patient-Centered Oncology Care® (PCOC) 2024.
Patient-Centered Oncology Care® (PCOC) 2024, a leading oncology conference, is set to convene in Nashville, Tennessee, from September 12th to 13th. This meeting will bring together top experts in the field to discuss cutting-edge advancements aimed at improving patient outcomes and quality of life in oncology care.
Samyukta Mullangi, MD, MBA, medical director at Thyme Care will be participating in a panel discussion about the new principal illness navigation codes (PIN) and their potential impact on the enhancing oncology model. The panel will discuss whether these codes will create a significant change in practice or if they are just a starting point.
This transcript has been lightly edited for clarity.
Transcript
What are you most looking forward to at Patient-Centered Oncology Care, or PCOC, next month?
I love the PCOC conference. Every year, I think it is such an opportunity to meet with industry leaders across oncology, thinking about where are the areas of innovation, interest, energy, investment, and really sharing notes.
I think there are not enough opportunities to be honest in terms of knowledge sharing, but AJMC's PCOC fulfills a really important niche in doing that. I think sharing best practices is just lifting all boats, so I'm very excited to see everybody.
Could you give a preview of what will be discussed during your panel, "The New Math: What Does PIN Mean to the Enhancing Oncology Model?"
Yeah, I'm in conversation with several community practice leaders talking about the new principal illness navigation codes that CMS introduced in January of this year. Those codes came with a big wave of excitement because formerly, there wasn't really a formal reimbursement structure for patient-oriented navigation, specifically. Even though there were sort of echoes of this within existing programs like the [Chronic Care Management] and [Principal Care Management programs], but I think there is a unique opportunity here.
What we're going to be talking about is whether these codes are going to create that wave of change, or whether they are a starting point, but potentially not enough to change practice. I think that's a very thorny and interesting conversation to get into so I'm really looking forward.
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays
June 19th 2025Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
2 Commerce Drive
Cranbury, NJ 08512